Multiple human tracking in RGB-depth data: A survey

© The Institution of Engineering and Technology. Multiple human tracking (MHT) is a fundamental task in many computer vision applications. Appearance-based approaches, primarily formulated on RGB data, are constrained and affected by problems arising from occlusions and/or illumination variations. In recent years, the arrival of cheap RGB-depth devices has led to many new approaches to MHT, and many of these integrate colour and depth cues to improve each and every stage of the process. In this survey, the authors present the common processing pipeline of these methods and review their methodology based (a) on how they implement this pipeline and (b) on what role depth plays within each stage of it. They identify and introduce existing, publicly available, benchmark datasets and software resources that fuse colour and depth data for MHT. Finally, they present a brief comparative evaluation of the performance of those works that have applied their methods to these datasets

Male breast cancer

Male breast cancer (MBC) is a rare disease representing less than 1% of all breast cancers (BC) and less than 1% of cancers in men. Age at presentation is mostly in the late 60s. MBC is recognized as an estrogen-driven disease, specifically related to hyperestrogenism. About 20% of MBC patients have family history for BC. Mutations in BRCA1 and, predominantly, BRCA2, account for approximately 10% of MBC cases. Because of its rarity, MBC is often compared with female BC (FBC). Based on age-frequency distribution, age-specific incidence rate patterns and prognostic factors profiles, MBC is considered similar to late-onset, postmenopausal estrogen/progesterone receptor positive (ER+/PR+) FBC. However, clinical and pathological characteristics of MBC do not exactly overlap FBC. Compared with FBC, MBC has been reported to occur later in life, present at a higher stage, and display lower histologic grade, with a higher proportion of ER+ and PR+ tumors. Although rare, MBC remains a substantial cause for morbidity and mortality in men, probably because of its occurrence in advanced age and delayed diagnosis. Diagnosis and treatment of MBC generally is similar to that of FBC. Men tend to be treated with mastectomy rather than breast-conserving surgery. The backbone of adjuvant therapy or palliative treatment for advanced disease is endocrine, mostly tamoxifen. Use of FBC-based therapy led to the observation that treatment outcomes for MBC are worse and that survival rates for MBC do not improve like FBC. These different outcomes may suggest a non-appropriate utilization of treatments and that different underlying pathogenetic mechanisms may exist between male and female BC

Prognostic value of the neutrophil/lymphocyte ratio in enteropancreatic neuroendocrine tumors

Supervivència lliure de progressió; Tumors neuroendocrinsSupervivencia libre de progresión; Tumores neuroendocrinosProgression-free survival; Neuroendocrine tumorsAccessible prognostic tools are needed to individualize treatment of neuroendocrine tumors (NETs). Data suggest neutrophil/lymphocyte ratios (NLRs) have prognostic value in some solid tumors, including NETs. In the randomized double-blind CLARINET study (NCT00353496; EudraCT 2005-004904-35), the somatostatin analog lanreotide autogel/depot increased progression-free survival (PFS) compared with placebo in patients with inoperable or metastatic intestinal and pancreatic NETs (grades 1–2, Ki-67  4; n = 25)]. Furthermore, NLRs were not prognostic in Cox models, irrespective of subgroups used. The therapeutic effect of lanreotide autogel/depot 120 mg was independent of NLRs (P > 0.1). These exploratory post-hoc analyses in patients with advanced intestinal and pancreatic NETs contrast with previous data suggesting NLR has prognostic potential in NETs. This may reflect the inclusion of patients with lower-grade tumors or use of higher NLR cutoff values in the current analysis.The CLARINET study was sponsored by Ipsen, the manufacturer of lanreotide autogel/depot. Medical writing services were provided by Nicky French PhD of Watermeadow Medical (Macclesfield, UK) – an Ashfield Company, part of UDG Healthcare plc – sponsored by Ipsen Ltd, Slough, UK in accordance with Good Publication Practice guidelines

Latest Pleistocene–Holocene Incremental Slip Rates of the Wairau Fault: Implications for Long‐Distance and Long‐Term Coordination of Faulting Between North and South Island, New Zealand

Abstract We use high‐resolution lidar microtopographic data and luminescence dating to constrain incremental Holocene–latest Pleistocene slip rates for the Wairau fault, a major dextral strike‐slip fault in the Marlborough Fault System, South Island, New Zealand. Our data come from two closely spaced study areas along the structurally simple, central portion of the fault: The well‐known Branch River terrace flight, and a previously undated series of offset risers and channel features several km to the east that we refer to as the Dunbeath site. Field work and mapping using lidar‐derived topography yields revised or novel measurements of nine fault offsets. We date those features using a post‐IR50‐IRSL225 infrared stimulated luminescence dating method, and a stratigraphically informed Bayesian age model. The dated slip history of the Wairau fault is further constrained using newly cataloged offset measurements collected along a ∼35 km stretch of the fault, and available paleoseismic data. Incremental slip rates are precisely computed using a Monte Carlo resampling scheme. Our results provide a nearly earthquake‐by‐earthquake record of incremental slip, with pronounced variations in incremental slip rate spanning multiple millennia and tens of m of slip. These extreme, multi‐millennial variations in fault slip rate have basic implications for earthquake occurrence, plate boundary lithosphere behavior, and probabilistic seismic hazard assessment